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Introduction
he assessment of bioavailability of oral hydrocortisone is 
complicated by its saturable binding in the therapeutic range to cortisol 
binding globulin (CBG). Ninety percent of serum cortisol circulates 
bound to cortisol binding globulin, 5% to generic binding proteins, 
such as albumin and α-1 glycoprotein, and only 5% is unbound or 
‘free’ [1]. CBG has high ainity for cortisol but lower capacity whereas 
albumin has a lower ainity and higher capacity and Lentjes and 
Romijn published Data from which free unbound cortisol could be 
calculated [2]. An increase in the free fraction results in an increase in 
clearance with dose and therefore less than dose proportional increases 
in C
max
 and bioavailability as measured by area under the curve (AUC) 
[3]. he only previous study of hydrocortisone bioavailability reported 
absolute bioavailability to be 0.96 (CI 0.82 to 1.09) [3], but used a 
radioimmunoassay to measure cortisol. Immunoassays have seen shown 
to give variable results depending on the speciicity and sensitivity of 
the antibody used and LC-MS/MS is now the gold standard method for 
measuring steroids [4].
he measurement of steroid hormones in saliva provides a non-
invasive method for assessing free steroid. Free cortisol is converted 
to cortisone by 11β hydroxy-steroid dehydrogenase (11βHSD) type 2 
which is highly expressed in salivary glands [5]. In serum, cortisol levels 
exceed cortisone and the ratio of cortisol to cortisone is approximately 
4:1 [6]. Free cortisol difuses into saliva where it is rapidly converted 
to cortisone as the salivary glands have a high level of 11βHSD type 2. 
hus, in saliva, the ratio of cortisol to cortisone is reversed compared to 
serum, with >4:1 salivary cortisone to cortisol [6]. Salivary cortisol and 
cortisone both show a close relationship to serum cortisol and serum 
free cortisol [6,7]. Ninety-four percent of the variation in serum cortisol 
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Abstract
Context: The assessment absolute bioavailability of oral hydrocortisone is complicated by its saturable binding 
to cortisol binding globulin (CBG). Previous assessment of bioavailability used a cortisol radioimmunoassay which 
has cross reactivity with other steroids. Salivary cortisone is a measure of free cortisol and LC-MS/MS is the gold 
standard method for measuring steroids. We here report the absolute bioavailability of hydrocortisone calculated 
using serum cortisol and salivary cortisone measured by LC-MS/MS. 
Methods: 14 healthy male dexamethasone suppressed volunteers were administered 20 mg hydrocortisone 
either intravenously or orally by tablet. Samples of serum and saliva were taken and measured for cortisol and 
cortisone by LC-MS/MS. Serum cortisol was corrected for saturable binding using published data and pharmacokinetic 
parameters derived using the program WinNonlin. 
Results: The mean (95% CI) bioavailability of oral hydrocortisone calculated from serum cortisol, unbound 
serum cortisol and salivary cortisone was 1.00 (0.89-1.14); 0.88 (0.75-1.05); and 0.93 (0.83-1.05), respectively. 
Conclusion:7KHGDWDFRQ¿UPWKDWDIWHURUDODGPLQLVWUDWLRQK\GURFRUWLVRQHLVFRPSOHWHO\DEVRUEHG7KHGDWD
derived from serum cortisol corrected for protein binding, and that from salivary cortisone, are similar supporting the 
FRQFHSWWKDWVDOLYDU\FRUWLVRQHUHÀHFWVVHUXPIUHHFRUWLVROOHYHOVDQGWKDWVDOLYDU\FRUWLVRQHFDQEHXVHGDVDQRQ
invasive method for measuring the pharmacokinetics of hydrocortisone.
is predicted from changes in salivary cortisone, salivary cortisone 
shows a closer relationship to serum cortisol than salivary cortisol, 
salivary cortisone is detectable at low levels of serum cortisol and can be 
measured in saliva without interference from oral hydrocortisone [6]. 
Here we report, for the irst time, absolute bioavailability of oral 
hydrocortisone measured using LC-MS/MS and a comparison of 
bioavailability derived from: total serum cortisol; calculated free serum 
cortisol; and salivary cortisone. 
Methods
Fourteen healthy male subjects with a median (IQR) age of 28 
(25-36) yrs, weight 83 (75-90) kg and BMI 25.3 (23.1-26.3) kg/m2 
participated in the study as previously reported [6]. he study was 
approved by the South-East Wales Research Ethics Committee and 
all the subjects have given written informed consent. Each subject was 
administered 20 mg oral hydrocortisone and 20 mg IV at 07:00 h in 
random order. Serum samples for cortisol and salivary samples for 
cortisol and cortisone were taken at – 10 min, 15 min, 30 min, 45 min, 
60 min, 1 h 15 min, 1 h 30 min, 2 h, 2 h 30 min, 3 h, 4 h, 5 h, 6 h, 8 h, 10 
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h and 12 h. Subjects received dexamethasone 1 mg orally at ~2200 h on 
Day 1 and at ~0600 h and ~1200 h on Day 2 during each study period 
to suppress the hypothalamic-pituitary-adrenal axis. All volunteers 
were given a standard mixed meal on Day 1 at 1900 h and on Day 2 at 
0800 h and 1300 h. 
Assays: LC-MS/MS analysis for serum, free and salivary cortisol/
cortisone was performed using a Waters Xevo TQ-MSTM mass 
spectrometer and a Waters AcquityTM LC system with an electrospray 
source operated in positive ionisation mode [8]. he lower limit of 
quantitation (LLOQ) for serum cortisol was 12.5 nmol/L. he inter-
assay imprecision was 8%, 7% and 6% at concentrations of 80 nmol/L, 
480 nmol/L and 842 nmol/L respectively. Salivary cortisol and cortisone 
were measured with a modiied LC-MS/MS assay with lower limits of 
detection 0.80 nmol/L (salivary cortisol) and 0.50 nmol/L (salivary 
cortisone). Intra-assay coeicient of variation (CV)s were less than 
9.3% and less than 7.9%; and inter-assay CVs were less than 9.7% and 
less than 10.3% at 1.8 nmol/L to 52.2 nmol/L of salivary cortisol and 3.6 
nmol/L to 96 nmol/L of salivary cortisone, respectively [9]. 
Data analysis
For the calculation of pharmacokinetic (PK) end-points, serum 
cortisol and salivary cortisol & cortisone concentrations below the 
limit of quantiication (BLQ) were assigned a value of zero. Total serum 
cortisol and salivary cortisone concentrations following either IV or 
oral hydrocortisone were adjusted by subtracting the – 10-min (min) 
sample, any adjusted values that were less than zero were set to zero. 
Serum cortisol was corrected for saturable binding using published 
data [2] to give an estimate of unbound serum cortisol (note in the 
design of the original study no plans were made to measure unbound 
plasma cortisol). Briely, this was achieved by extracting and plotting 
data on free fraction with plasma cortisol and deriving a polynomial 
function to describe the fraction unbound (fu) at diferent plasma 
cortisol concentrations. For each total plasma cortisol concentration, 
the corresponding fu was calculated and used to derive the unbound 
plasma cortisol concentration. he PK end-points, C
max
, AUC
0-inf
, T
max 
were derived from the individual total serum cortisol, unbound serum 
cortisol or salivary cortisone concentration-time data over 0-12 h 
using Non-compartmental analysis in WinNonlin Phoenix 32. In the 
case of a deviation from the theoretical time, the actual time of blood 
sample was used in the calculation. Any individual treatment proiles 
from subjects where the pre-dose cortisol demonstrates inadequate 
suppression were excluded.
Bioavailability for each individual was calculated from the IV and 
oral AUC
0-inf 
values using logarithmic transformation data, analysed 
using a ixed afects general linear model accounting for sequence and 
treatment. he geometric mean and 95% conidence interval around 
the geometric mean were calculated for bioavailability for each of total 
serum cortisol, unbound serum cortisol and salivary cortisone values.
Results
he concentration-time proiles of serum cortisol, calculated 
unbound free serum cortisol and salivary cortisone are presented in 
the Figure 1 and the results from the pharmacokinetic analysis showing 
key parameters and variability in Table 1. he proiles for all three 
measures of cortisol were similar and the time of C
max
 was the same 
for salivary cortisone as for serum cortisol. As would be expected the 
C
max 
for IV is greater than that of oral hydrocortisone. Examining the 
variability in terms of CV% around each set of data in terms of AUC
0-
inf
, most variability is seen for the calculated unbound serum cortisol 
(46% iv, 50% oral) and least for salivary cortisone (22% IV, 20% oral), 
similar results were seen for the C
max
. he absolute bioavailability of 
hydrocortisone was not statistically diferent for the three methods of 
measurement but for the calculated unbound and salivary cortisone 
the absolute bioavailability was <100% (88% and 93%, respectively) 
whereas for total serum cortisol it was 100%.
Discussion
We have shown that oral hydrocortisone is completely absorbed 
with an absolute bioavailability of 100% when calculated from total 
Figure 1:3KDUPDFRNLQHWLF¿JXUHVIRUA. Total serum cortisol; B. Calculated unbound serum cortisol; C. Salivary cortisone following oral or IV administration of 
20 mg hydrocortisone.
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serum cortisol and is not statistically diferent from 100% when 
calculated using unbound serum cortisol or salivary cortisone. he 
results using LC-MS/MS in our study conirm those previously 
published by Derendorf et al., who determined a bioavailability of 96 
± 20% using a radioimmunoassay [3]. he mean total plasma AUC of 
1009 ± 383 ng/ml*h, C
max
 of 319 ± 109 ng/ml and median T
max
 of 1.125 
h (0.5-1.5 h) from this study was similar to that reported by Derendorf 
et al of 1163 ng/ml*h, 305 ± 57 ng/ml, and 1.2 h (0.4-2 h) respectively, 
following a 20 mg oral dose. he results for C
max
 and T
max
 for 20 mg 
hydrocortisone are also in agreement with other previously published 
studies showing a range of 225-285 ng/ml ater 1-1.4 h [10].
he absolute bioavailability was non-signiicantly lower for 
calculated unbound and salivary cortisone at 88 and 93%. his is not 
surprising, as due to non-linear and saturable protein binding, free 
cortisol levels will be higher immediately ater IV administration 
compared to the oral route. his will potentially lead to higher 
total clearance and lower AUC
0-inf 
of the IV compared to the oral 
formulation especially at the early time points leading to an over-
estimation of the bioavailability. his illustrates the potential problem 
of conducting bioavailability studies where there is non-linearity in 
the pharmacokinetics of a drug, these issues have been previously 
identiied [11]. In the case of hydrocortisone either the unbound 
plasma cortisol or the salivary cortisone (as a surrogate for unbound 
plasma cortisol) concentrations will more likely give a more accurate 
assessment of absolute bioavailability compared to using total plasma 
cortisol concentrations. From our own observations, the diferences 
in bioavailability for hydrocortisone do not seem to be signiicantly 
afected by the non-linear protein binding.
One limitation of the current study is that individual total serum 
cortisol concentration-time data were used to calculate the unbound 
cortisol proiles based on a literature derived model, errors introduced 
here may have contributed to the higher variability seen in the data. 
Ideally further research is needed where the actual unbound plasma 
cortisol is measured for each individual prior to data analysis and 
calculation of bioavailability. Interestingly least variability was 
observed in the salivary cortisone data suggesting that for this drug 
the data from this measure is reliable for calculating bioavailability. 
Another limitation is the 2 × 2 nature of this study design which may 
limit the detection of intra-individual variability and also detection of 
possible carry over efects [12].
Conclusion
In conclusion, this paper demonstrates the use of alternative 
approaches in the determination hydrocortisone bioavailability that 
overcome the issue of non-linear pharmacokinetics of the drug due to 
non-linear protein binding. Atypical pharmacokinetics may inluence 
the results when determining bioavailability and should thus be 
considered at the study design stage. he results conirm that salivary 
cortisone relects unbound serum cortisol levels and demonstrate that 
salivary cortisone can be used clinically as a non-invasive method for 
measuring cortisol exposure ater hydrocortisone administration. his 
is especially of value in monitoring children with adrenal insuiciency 
to check for appropriate hydrocortisone replacement [13].
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Route Measure AUC
0-inf 
(nmol/L.h) Mean ± SD) C
max
 (nmol/L) Mean ± SD T
max
 (h) Median and range Bioavailability GeoMean and Cl GM
IV Total serum cortisol 2900 ± 926 1629 ± 491
Oral Total serum cortisol 2779 ± 1058 880 ± 302 1.125 (0.5-1.5) 1.0 (0.89-1.14)
IV
Unbound serum 
cortisol
391 ± 182 386 ± 167
Oral
Unbound serum 
cortisol
391 ± 165 153 ± 81 1.125 (0.5-1.5) 0.88 (0.75-1.05)
IV Salivary Cortisone 258 ± 58 142 ± 22
Oral Salivary Cortisone 239 ± 48 88 ± 17 1.0 (0.75-1.5) 0.93 (0.83-1.05)
Table 1: Pharmacokinetic parameters derived from measurement of serum cortisol, calculated unbound serum cortisol and salivary cortisone following oral and iv 
administration of 20 mg hydrocortisone.
